Skip to main content

Abstract

There is a growing body of literature using SBRT in the re-irradiation setting for locally recurrent H&N tumors. Doses vary, with best results/lowest toxicity ≥35 Gy in five fractions, given on alternating days. Toxicity rates of SBRT appear to be lower than with conventional techniques; however severe acute and late toxicities remain a challenge.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Vargo JA, Ferris RL, Ohr J, et al. A prospective phase 2 trial of reirradiation with stereotactic body radiation therapy plus cetuximab in patients with previously irradiated recurrent squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2015;91:480–8.

    Article  PubMed  Google Scholar 

  2. Comet B, Kramar A, Faivre-Pierret M, et al. Salvage stereotactic reirradiation with or without cetuximab for locally recurrent head-and-neck cancer: a feasibility study. Int J Radiat Oncol Biol Phys. 2012;84:203–9.

    Article  PubMed  Google Scholar 

  3. Vargo JA, Wegner RE, Heron DE, et al. Stereotactic body radiation therapy for locally recurrent, previously irradiated nonsquamous cell cancers of the head and neck. Head Neck. 2012;34:1153–61.

    Article  PubMed  Google Scholar 

  4. Heron DE, Ferris RL, Karamouzis M, et al. Stereotactic body radiotherapy for recurrent squamous cell carcinoma of the head and neck: results of a phase I dose-escalation trial. Int J Radiat Oncol Biol Phys. 2009;75:1493–500.

    Article  PubMed  Google Scholar 

  5. Ling DC, Vargo JA, Heron DE. Stereotactic body radiation therapy for recurrent head and neck cancer. Cancer J. 2016;22:302–6.

    Article  CAS  PubMed  Google Scholar 

  6. Ling DC, Vargo JA, Ferris RL, et al. Risk of severe toxicity according to site of recurrence in patients treated with stereotactic body radiation therapy for recurrent head and neck cancer. Int J Radiat Oncol Biol Phys. 2016;95:973–80.

    Article  PubMed  Google Scholar 

  7. Owen D, Iqbal F, Pollock BE, et al. Long-term follow-up of stereotactic radiosurgery for head and neck malignancies. Head Neck. 2015;37:1557–62.

    Article  PubMed  Google Scholar 

  8. Rwigema JC, Heron DE, Ferris RL, et al. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy. Am J Clin Oncol. 2011;34:372–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Editor information

Editors and Affiliations

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Judy, G.D., Chera, B.S. (2018). Re-irradiation. In: Kaidar-Person, O., Chen, R. (eds) Hypofractionated and Stereotactic Radiation Therapy. Springer, Cham. https://doi.org/10.1007/978-3-319-92802-9_16

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92802-9_16

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92800-5

  • Online ISBN: 978-3-319-92802-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics